RIGL FY 2022 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$541M

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$120M-19.4% YoY

Gross Profit

$118M98.5% margin

Operating Income

-$56M-46.2% margin

Net Income

-$59M-48.7% margin

EPS (Diluted)

$-3.40

Cash Flow

Operating Cash Flow

-$74M

Free Cash Flow

-$74M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$134M

Total Liabilities

$148M

Stockholders' Equity

-$14M

Cash & Equivalents

$24M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$120M	$149M	-19.4%
Gross Profit	$118M	$148M	-20.0%
Operating Income	-$56M	-$12M	-344.5%
Net Income	-$59M	-$18M	-227.0%